Aesha I. Ali
YOU?
Author Swipe
View article: Beyond hemostasis: Factor VIII deficiency impacts hematopoietic stem cells development in zebrafish
Beyond hemostasis: Factor VIII deficiency impacts hematopoietic stem cells development in zebrafish Open
Introduction Hemophilia A (HA) is a monogenic bleeding disorder caused by coagulation Factor (F) VIII deficiency. Recent studies suggest that FVIII function may extend beyond hemostasis. In a previous study, we utilized morpholino antisens…
View article: Genetic background of primary and familial HLH in Qatar: registry data and population study
Genetic background of primary and familial HLH in Qatar: registry data and population study Open
Background Familial hemophagocytic lymphohistiocytosis (FHLH) is an inherited life-threatening disease. Five types are identified, with the addition of congenital immunodeficiency syndromes in which HLH is a typical manifestation. The lite…
View article: Upregulation of interferon signaling predicts sustained complete remission in pediatric AML patients
Upregulation of interferon signaling predicts sustained complete remission in pediatric AML patients Open
The immunological composition of the microenvironment has shown relevance for diagnosis, prognosis, and therapy in solid tumors, while it remains underexplored in acute leukemias. In this study, we investigated the significance of the acut…
View article: Serological Prevalence of Latent Epstein-Barr Virus Infection in Children and Adolescents
Serological Prevalence of Latent Epstein-Barr Virus Infection in Children and Adolescents Open
Background: Epstein-Barr Virus (EBV), first discovered in 1946, is one of the most common viruses, which found over the world causing latent infection or different undistinguishable symptoms ranged from mild to severe. This prevalence and …
View article: Genetic background of FHLH in Qatar: Registry data and population study
Genetic background of FHLH in Qatar: Registry data and population study Open
Background Familial Hemophagocytic Lymphohistiocytosis (FHLH) is an inherited life-threatening disease. Five types are identified with the addition of congenital immunodeficiency syndromes in which HLH is a typical manifestation. The liter…
View article: Genetic background of FHLH in Qatar: Registry data and population study
Genetic background of FHLH in Qatar: Registry data and population study Open
Background The Familial Hemophagocytic Lymphohistiocytosis (FHLH) is an inherited life-threatening disease. Five types are identified with the addition of congenital immunodeficiency syndromes in which HLH is a typical manifestation. The l…
View article: Supplementary Figure 6 from Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting
Supplementary Figure 6 from Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting Open
Cytokines present in serum of ACTIV-treated mice.
View article: Data from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer
Data from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer Open
Purpose:In this article, we describe a combination chimeric antigen receptor (CAR) T-cell therapy that eradicated the majority of tumors in two immunocompetent murine pancreatic cancer models and a human pancreatic cancer xenograft model.E…
View article: Supplementary Figure 1 from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer
Supplementary Figure 1 from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer Open
Supplementary Figure 1. Panc02-Her2, KPC-Her2 and 24JK-Her2 cells express comparable levels of Her2.
View article: Supplementary Figure 8 from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer
Supplementary Figure 8 from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer Open
Supplementary Figure 8. Proposed mechanisms and clinical application for the ACTIV+Pano treatment.
View article: Supplementary Figure 4 from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer
Supplementary Figure 4 from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer Open
Supplementary Figure 4. Pano did not enhance the cytotoxicity of CARaMEL cells nor oncolysis of VV-gp100.
View article: Data from Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting
Data from Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting Open
Purpose: While adoptive transfer of T cells bearing a chimeric antigen receptor (CAR) can eliminate substantial burdens of some leukemias, the ultimate challenge remains the eradication of large solid tumors for most cancers. We aim…
View article: Supplementary Figure 6 from Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting
Supplementary Figure 6 from Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting Open
Cytokines present in serum of ACTIV-treated mice.
View article: Supplementary Figure 3 from Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting
Supplementary Figure 3 from Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting Open
CAR T cells lacking the pMEL TCR are less effective than CARaMEL T cells at inhibiting tumor growth.
View article: Supplementary Figure 1 from Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting
Supplementary Figure 1 from Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting Open
Dual-specific T cells respond against both gp100 and Her2.
View article: Supplementary Figure 5 from Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting
Supplementary Figure 5 from Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting Open
CARaMEL T cells persist in long term surviving mice.
View article: Supplementary Figure 2 from Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting
Supplementary Figure 2 from Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting Open
High dose IL-2 enables durable tumor regression and proliferation of T cells.
View article: Supplementary Figure 5 from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer
Supplementary Figure 5 from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer Open
Supplementary Figure 5. Pano did not alter Her2 or H2-Db expression on Panc02-Her2 tumor cells in vivo and CARaMEL cells were detectable over 100 days in ACTIV+ Pano treated mice.
View article: Supplementary Figure 4 from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer
Supplementary Figure 4 from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer Open
Supplementary Figure 4. Pano did not enhance the cytotoxicity of CARaMEL cells nor oncolysis of VV-gp100.
View article: Supplementary Figure 3 from Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting
Supplementary Figure 3 from Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting Open
CAR T cells lacking the pMEL TCR are less effective than CARaMEL T cells at inhibiting tumor growth.
View article: Supplementary Figure 2 from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer
Supplementary Figure 2 from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer Open
Supplementary Figure 2. Pancreatic cells are resistant to VV-gp100 oncolysis but sensitive to CAR T cell-mediated cytotoxicity.
View article: Supplementary Figure 5 from Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting
Supplementary Figure 5 from Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting Open
CARaMEL T cells persist in long term surviving mice.
View article: Supplementary Figure 7 from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer
Supplementary Figure 7 from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer Open
Supplementary Figure 7. No cytokine storm was observed in WAP- and MMTV-Her2 mice post the ACTIV+Pano treatment.
View article: Supplementary Figure 3 from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer
Supplementary Figure 3 from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer Open
Supplementary Figure 3. Pano induced pancreatic tumor cell apoptosis.
View article: Supplementary Figure 2 from Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting
Supplementary Figure 2 from Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting Open
High dose IL-2 enables durable tumor regression and proliferation of T cells.
View article: Supplementary Figure 5 from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer
Supplementary Figure 5 from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer Open
Supplementary Figure 5. Pano did not alter Her2 or H2-Db expression on Panc02-Her2 tumor cells in vivo and CARaMEL cells were detectable over 100 days in ACTIV+ Pano treated mice.
View article: Supplementary Figure 3 from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer
Supplementary Figure 3 from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer Open
Supplementary Figure 3. Pano induced pancreatic tumor cell apoptosis.
View article: Supplementary Figure 7 from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer
Supplementary Figure 7 from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer Open
Supplementary Figure 7. No cytokine storm was observed in WAP- and MMTV-Her2 mice post the ACTIV+Pano treatment.
View article: Data from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer
Data from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer Open
Purpose:In this article, we describe a combination chimeric antigen receptor (CAR) T-cell therapy that eradicated the majority of tumors in two immunocompetent murine pancreatic cancer models and a human pancreatic cancer xenograft model.E…
View article: Supplementary Figure 6 from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer
Supplementary Figure 6 from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer Open
Supplementary Figure 6. The infiltration of CD8+ cells to the Her2+ non-tumor regions.